ID   RERF-LC-A1/hPDPN
AC   CVCL_D2U4
SY   RERF-LC-AI/hPDPN
RX   PubMed=25080943;
RX   PubMed=28387591;
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln104Ter (c.310C>T); ClinVar=VCV000566924; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 29602; PDPN.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4402 ! RERF-LC-A1
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 30-01-24; Version: 1
//
RX   PubMed=25080943; DOI=10.1038/srep05924;
RA   Kato Y., Kaneko M.K.;
RT   "A cancer-specific monoclonal antibody recognizes the aberrantly
RT   glycosylated podoplanin.";
RL   Sci. Rep. 4:5924-5924(2014).
//
RX   PubMed=28387591; DOI=10.1089/mab.2017.0001;
RA   Yamada S., Ogasawara S., Kaneko M.K., Kato Y.;
RT   "LpMab-23: a cancer-specific monoclonal antibody against human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 36:72-76(2017).
//